Navigation Links
Hematologic in Medical News

5- and 10-year survival continues to improve for US children with hematologic malignancies

5- and 10-year survival rates continue to improve for children under the age of 15 who are diagnosed with acute lymphoblastic leukemia (ALL), acute non-lymphoblastic leukemia, or non-Hodgkin lymphoma (NHL) in the United States, researchers report in the September 9 online issue of the Journal of ...

Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Multiple Myeloma

...rall survival and safety. Dr. Kenneth Anderson, Chief, Division of hematologic Neoplasia, Dana-Farber Cancer Institute, commented, "Perifosine holds great...ncurable but treatable disease. Multiple myeloma is the second most-common hematologic cancer, representing 1% of all cancer diagnoses and 2% of all cancer deaths...

Millennium Pharmaceuticals Inc./Lymphoma Research Foundation funds lymphoma research

...targets. We are delighted that Dr. Fu has chosen MCL as the focus of his Clinical Career Development Project," stated Michael Williams, MD, Director, hematologic Malignancy Program - University of Virginia and Chair of LRF's Mantle Cell Consortium The 3-year Clinical Investigator Career Development Award is ...

Sunesis Pharmaceuticals Appoints Helen S. Kim to Board of Directors

...cals Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of hematologic and solid cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, vore...

Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer

...t ovarian cancer or AIDS-related Kaposi's sarcoma, hematologic toxicity (based on platelet count or absolute neut...OXIL In patients with multiple myeloma, hematologic toxicity (based on platelet count, absolute neutro...toxicity of other anticancer therapies, especially hematologic toxicities, when used in combination with other th...

Six Researchers to Receive Prestigious Awards from the American Society of Hematology

...e world's largest professional society of blood specialists, will honor six scientists who have made significant contributions to the understanding of hematologic diseases. These awards, including the newly created Ernest Beutler Lecture and Prize, will be presented at the 51st ASH Annual Meeting taking place De...

Sunesis Pharmaceuticals Receives Milestone Payment From Biogen Idec

...mmercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today announced that it has received a $1.5 million milestone paym...mmercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development org...

Fate Therapeutics to Present Data on Stimulation of Osteogenic Activity Using Small Molecule Modulators of Wnt Pathway

... FT1050, a small molecule SCM designed to increase hematopoietic stem cell number and function in dual umbilical cord blood transplant recipients with hematologic malignancies. In addition, Fate Therapeutics and Stemgent have formed an alliance - CATALYST - a collaborative program to provide its members with fi...

NCI Renews Mayo Clinic Cancer Center Support Grant, Extends Comprehensive Status

... faculty across all three sites are organized into programs that focus on 12 key cancer research themes. They include Women's Cancers, Neuro-Oncology, hematologic (bloodborne) Malignancies, Gene and Virus Therapy, Developmental Therapeutics, Genetic Epidemiology and Risk Assessment, Immunology and Immunotherapy,...

NCI renews Mayo Clinic Cancer Center support grant, extends comprehensive status

... faculty across all three sites are organized into programs that focus on 12 key cancer research themes. They include Women's Cancers, Neuro-Oncology, hematologic (bloodborne) Malignancies, Gene and Virus Therapy, Developmental Therapeutics, Genetic Epidemiology and Risk Assessment, Immunology and Immunotherapy,...
Hematologic in Medical Technology

Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome

- Results Presented at ASH Annual Meeting- SAN FRANCISCO, Dec. 6 /PRNewswire-FirstCall/ -- Sanofi-aventis today announced results of a randomized phase III study presented at the 50th Annual Meeting of the American Society of Hematology. The study in adult patients with hematological mali...

Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors

HDAC Inhibitor MGCD0103 Demonstrates substantial Response Rate in Two Clinical Trials Clinical Data Presented on Pilot Pharmacokinetic Study of Oral Azacitidine Exelixis Reports Comprehensive XL880 Phase I Data At ASCO Exelixis Reports Integrated Data From Phase II Clinical Trials of XL999 a...

Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial

GERMANTOWN, Md., June 13, 2007 /PRNewswire-FirstCall/ -- Avalon Pharmaceuticals, Inc. , today announced that it is will provide an update on the Phase I clinical trial of AVN944 in hematologic malignancies on Tuesday, June 19, 2007, after the close of the U.S. financial markets. The Company will a...

Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing

...data to date suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Results to date suggest that hematologic events are common but manageable. Kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) are less frequent and less severe than is common...

National Cancer Institute Research Identifies Unique Mechanism of Brostallicin's Anti-Tumor Effectiveness

...th. More than 200 patients have been treated with brostallicin in single-agent and combination studies. Brostallicin had predictable and predominantly hematologic toxicities. Activity was demonstrated in a number of solid tumor types. A phase II study of brostallicin in relapsed/refractory soft tissue sarcoma me...

SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

...openia, have been infrequently reported with SIMPONI in clinical trials. Discontinuation of SIMPONI should be considered in patients with significant hematologic abnormalities. The concurrent administration of TNF-antagonists with anakinra or abatacept is not recommended. Concurrent administration has b...

Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL

... Loaie M. El-Helw of the Weston Park Hospital, Sheffield UK. The review focuses on the impressive preclinical anti-tumor activity demonstrated in hematologic cancers over standard anthracyclines and the rational design modifications to the chemical compound believed to be responsible for enhanced DNA damage...

Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting

...ble proteasome inhibitors being developed by Proteolix for the treatment of hematologic malignancies and solid tumors. Data from the Phase 2 clinical trial ...se 2 clinical trials, carfilzomib has demonstrated single-agent activity in hematologic malignancies and solid tumors, including multiple myeloma, Waldenstrom's ma...

Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting

... being developed by Proteolix for the treatment of hematologic malignancies and solid tumors. "In these cl...rfilzomib as a promising new protease inhibitor in hematologic and solid tumor malignancies. Carfilzomib is well...filzomib has demonstrated single-agent activity in hematologic malignancies and solid tumors, including multiple ...

Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer

...ropathy-sparing alternative to FOLFOX (p<0.0019). With regard to hematologic toxicities, thrombocytopenia and neutropenia were more frequent and severe ...than 1,100 patients have received picoplatin. To date, results suggest that hematologic events are severe but manageable. Kidney toxicity (nephrotoxicity) and nerv...
Hematologic in Medical Products

Pocket Guide to Chemotherapy Protocols, 2nd Edition

Features:... Completely revised and updated Contains combination as well as selected single-agent regimens for solid tumors and hematologic malignancies The regimens selected are based on the published literature and are used in clinical practice in the medical oncology community ...
Company:Skyscape, Inc.
Hematologic in Medical Dictionary

Thalassemia

...ew importance to adult ... Hemoglobin E-beta thalassemia is seen with increasing frequency and poses a ... Testing for α- thalassemia includes: hematologic testing of red blood cell ... Alpha- thalassemia is usually inherited in an autosomal recessive manner. ... Thalassemia is an inherited d...

Splenomegaly

... splenomegaly is usually defined as a spleen ex ... study evaluating splenomegaly in 2056 patients who ... massive splenomegaly , 31% had a hematologic disorder, ... Splenomegaly . VIDEO: Chemo booster cuts treatment time by ... Splenomegaly . Definition: Splenomegaly is an enlargement of th...

Oncology

...e than a trebling of risk of contralateral breast ... Specialty > Oncology > Breast Cancer ... Gynecologic Oncology Center. Center for hematologic Malignancies ... Urologic Oncology Center. Screening, Prevention and Early Detection. Technologies for Treatment ... ...

Myeloproliferative Disorders

...t) mailing list ... The NCI PDQ patient statement on Myeloproliferative Disorders ... Myeloproliferative disorders , or MPD, are a group of hematologic (blood) ... Myeloproliferative Disorders (MPD) Advances in the Treatment in Myeloma ... The recent discovery of a key gene mutation has la...

Genetics

...Department of Molecular Genetics & Microbiology ... All News and Articles> ... How Genzyme Can Help You Do More to Personalize TestingFor hematologic and solid tumor malignancies, Genzyme provides an Antibody Library, and a FISH Probe Library. ... ... to the Genetics Program at ... The inter...

Anemias

...nthesis. ... Anemias in which the MCV is 80 to 100 femtoliters. Normocytic anemia is often ... Sideroblastic anemias also occur secondary to hematologic malignancies (eg, ... Anemias are caused by either excess red cell destruction, or underproduction of ... The megaloblastic anemias often pr...
Hematologic in Biological News

Tumor-inhibiting protein could be effective in treating leukemia

...said. "We decided we wanted to look to see if Angiocidin had any effect on hematologic malignancy, and we chose leukemia." Tuszynski said leukemia cells arise ...a new therapeutic application for this protein, that it could differentiate hematologic malignancies into a normal-like state, allowing then for chemotherapy becau...

Ireland Cancer Center researchers advance stem cell gene therapy

... this promising research, Ireland Cancer Center scientists presented 24 oral and poster presentations at ASH. The breadth and depth of this innovative hematologic research at the Ireland Cancer Center are outstanding, says Alvin Schmaier, MD, Chief of Hematology/Oncology at UHCMC and Case Western Reserve Univers...

NCI renewal grant to develop new cancer therapies

... mode of action of these agents to make them even more effective in various hematologic malignancies by rationally combining them with other molecularly targeted a...easome and IKK beta inhibitors in the treatment of acute leukemia and other hematologic malignancies." Grant and his team are already leading a multi-institut...

Daisies lead scientists down path to new leukemia drug

...ast progress in the drug development world, said Craig T. Jordan, Ph.D., senior author of the Blood article and director of Translational Research for hematologic Malignancies at the James P. Wilmot Cancer Center, at the University of Rochester Medical Center. Clinical trials are expected to begin in England ...

UNC study questions FDA genetic-screening guidelines for cancer drug

.... The authors recommended that the FDA amend the product information for irinotecan to describe the association between irinotecan dose and risk of hematologic toxicity among patients with two UGT1A1*28 genes. ...

Massey researchers induce cell death in leukemia

...ing body of preclinical and early clinical data suggesting interactions between HDAC inhibitors and bortezomib in other tumor cell types, particularly hematologic malignancies -- is certainly of interest and warrants further investigation as a potential therapeutic strategy in CLL." ...

Knocking out survival protein could aid leukemia treatment

...effective target for drugs directed against CLL and ALL," says principal investigator John C. Byrd, professor of internal medicine and director of the hematologic malignancies program at Ohio State's James Cancer Hospital and Solove Research Institute. "These results give us a rationale for lowering the am...

Customized gene chip provides rapid detection of genetic changes in children's cancer

...may help confirm a clinical diagnosis, said Saul Surrey, Ph.D., professor of medicine and Associate Director of Research at the Cardeza Foundation for hematologic Research and the Division of Hematology at Jefferson Medical College. If a clinical diagnosis isn't known, the method might provide some clues. The...

Leukemia Drug Breakthrough Study In New England Journal Of Medicine

... Alan List, M.D., leader of the hematologic Malignancies Program at the H. Lee Moffitt Cancer Center & Research Institute, recently conducted a phase I/II trial of the experimental drug Revl...
Hematologic in Biological Technology

AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma

...Multiple Myeloma Multiple myeloma, a cancer of the plasma cell, is an incurable but treatable disease. Multiple myeloma is the second most-common hematologic cancer, representing 1% of all cancer diagnoses and 2% of all cancer deaths. According to the American Cancer Society, in 2009, there will be an estim...

Sunesis Receives Approval for Listing on The NASDAQ Capital Market

...mmercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today announced that NASDAQ has approved its application to transf...mmercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development org...

Sunesis Reports Financial Results for the Second Quarter 2009

... Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, voreloxin, in ...

Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia

...ally lower (13 per cent vs. 25 per cent) Elacytarabine is a novel cytotoxic agent being developed by Clavis Pharma for the treatment of hematologic cancers and solid tumors, especially those resistant to existing agents. One particularly difficult-to-treat patient group is late-stage acute myeloid...

Sunesis to Present at the Jefferies 3rd Annual Healthcare Conference

...mmercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today announced that Daniel Swisher, Chief Executive Officer of Su...mmercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development org...

Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association

...ble proteasome inhibitors being developed by Proteolix for the treatment of hematologic malignancies and solid tumors. Relapsed Multiple Myeloma Patients A...se 2 clinical trials, carfilzomib has demonstrated single-agent activity in hematologic malignancies and solid tumors, including multiple myeloma, Waldenstrom's ma...

Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients

...e.g., persistent fever, bruising, bleeding, pallor) while on CIMZIA. Consider discontinuation of CIMZIA therapy in patients with confirmed significant hematologic abnormalities. An increased risk of serious infections has been seen in clinical trials of other TNF blocking agents used in combination with an...

Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting

...t ovarian cancer or AIDS-related Kaposi's sarcoma, hematologic toxicity (based on platelet count or absolute neut...IL In patients with multiple myeloma, hematologic toxicity (based on platelet count, absolute neutro...toxicity of other anticancer therapies, especially hematologic toxicities, when used in combination with other th...

Quest Diagnostics to Present Genomic Studies Related to New Testing Techniques for Leukemia and Prostate Cancer at 2009 ASCO Meeting

...and services. "As a leader in diagnostics for hematologic cancers, we believe our studies will help investig...ble to doctors for directly identifying markers of hematologic cancers in blood plasma rather than painfully extr...id tumors, such as prostate cancer, as well as for hematologic cancers. In addition, in February 2009, the compan...

Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting

...ptosis in cancer cells with minimal off-target effects. In Phase 1 and Phase 2 clinical trials, carfilzomib has demonstrated single-agent activity in hematologic malignancies and solid tumors, including multiple myeloma, Waldenstrom's macroglobulinemia, mantle cell lymphoma, and renal cell carcinoma. Pro...
Other Tags
(Date:7/13/2014)... 2014 The report “Micronutrient Market ... Form (Chelated & Non Chelated), Application Mode (Soil, ... Trends and Forecast to 2018” defines and segments ... and forecasting of the global value and volume ... and restraining factors for the global agriculture micronutrients ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 MarketsandMarkets ... Market [3D Modeling; 3D Scanning; 3D rendering; Layout ... and Analysis (2013 - 2018)”, which analyzes and ... in North America, Western Europe, Eastern Europe, Middle ... report also draws the competitive landscape of the ...
(Date:7/13/2014)... WA (PRWEB) July 13, 2014 Athletes ... longer recovery period from concussions, according to research presented ... ( AOSSM ) Annual Meeting. The research marks the ... concussion based on the known physical events that occur ... patients with a long allele in the (GT)n genotype ...
(Date:7/13/2014)... MyDressCity.com, one of the most popular suppliers of wedding ... new range of elegant Quinceanera dresses . What’s ... prices. Worldwide clients can enjoy this special offer before ... shop, there are plenty of beautiful dresses for sale, ... MyDressCity.com’s hot items are prom gowns, bridesmaid gowns, wedding ...
(Date:7/13/2014)... 13, 2014 A decreased ability to identify ... and Alzheimer,s disease, while examinations of the eye ... associated with Alzheimer,s, in the brain, according to ... at the Alzheimer,s Association International Conference 2014 (AAIC ... studies, the decreased ability to identify odors was ...
Breaking Medicine News(10 mins):Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 4Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7
(Date:7/11/2014)... other group members to reduce aggression and gain access ... for grooming activities shows a certain pattern across the ... journal Biology Letters . , Grooming between individuals ... ulterior motives. To be groomed has hygienic benefits and ... individual can provide access to infants, mating opportunities and ...
(Date:7/11/2014)... 11, 2014 Researchers have pioneered a revolutionary ... new technology, called Virtual Finger, allows scientists to ... neurons and synapses using the flat surface of ... 3D imaging studies orders of magnitude more efficient, ... level across many areas of experimental biology. The ...
(Date:7/11/2014)... hippocampus, the marginal division of the striatum is ... the impact degree of substance P in the ... Yan Yu and his team, College of Biophotonics, ... staining, that substance P receptor, neurokinin 1 was ... division of normal rats. Unilateral or bilateral injection ...
Breaking Biology News(10 mins):Baboons groom early in the day to get benefits later 2Virtual finger enables scientists to navigate and analyze complex 3D images 2
Other Contents